Drug class in one race
BCL-2 drugs for Multiple Myeloma
3 tracked BCL-2 drugs in the Multiple Myeloma race. The class explanation lives on the BCL-2 page; the full indication pipeline across every mechanism is on the Multiple Myeloma page.
2 Phase 1/21 Phase 1
Head-to-head evidence: APG-2575(Lisaftoclax ) vs LOXO-338 · APG-2575(Lisaftoclax ) vs Surzetoclax · LOXO-338 vs Surzetoclax